News

Sanofi-aventis said that the aim of the research partnership with Aviesan is to enhance scientific knowledge in the areas of life sciences and healthcare, to develop projects benefiting

Rituxan is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL.

The discontinuance of manufacturing operations is scheduled to take place by the end of March 2010. Taro Ireland plans to continue to maintain the physical plant in good

Opko has acquired Pharmacos Exakta, including a manufacturing facility owned by an affiliate, for cash and shares of Opko Common Stock. Phillip Frost, chairman and CEO of Opko,

HealthLinx said that the study will be run in two stages, stage one of the study is expected to commence late 1st quarter early second quarter this year

Both the companies are evaluating the complete response letter, in which the FDA has indicated that a preclinical finding of pancreatic acinar cell tumors in rats was of

Dynavax and GSK said that the selected molecule has moved into advanced preclinical IND-enabling studies that could allow clinical development to begin as early as this year. As

The funding will be directed towards the first phase of a two year translational programme to take human retinal progenitor cells (hRPCs) towards the clinic in the US,

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Reportedly, Roche has started a 24 weeks Phase 2b study